Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
The University of Sydney · Royal North Shore Hospital · +18 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
933
total citations
- FWCI
- 48.75
- Percentile
- 100%
- References
- 26
Citations per year
Authors
18- GVGeorgina V. LongCorresponding
The University of Sydney, Royal North Shore Hospital, Melanoma Institute Australia
- RDReinhard Dummer
University Hospital of Zurich
- OHOmid Hamid
Angeles Clinic and Research Institute
- TFThomas F. Gajewski
University of Chicago Medical Center
- CCChristian Caglevic
Universidad del Desarrollo, Clínica Alemana
Topics & keywords
Topics
Keywords
- Pembrolizumab
- Medicine
- Placebo
- Internal medicine
- Population
- Oncology
- Discontinuation
- Melanoma
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.